Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: Association with extranodal site, NK or Tγδ phenotype, anaplastic morphology and CD30 expression
Data
2000Soggetto
Abstract
Most peripheral T-cell lymphomas (PTCL) express the αβ T-cell receptor (TCR) whereas rare PTCL express the γδ TCR. Most if not all γδ PTCL are extranodal lymphomas and among them, hepatosplenic γδ PTCL constitute a distinct clinicopathological entity. Besides αβ and γδ PTCL, there is a recently recognized group of extranodal, mainly nasal tumours, which display, in most instances, phenotypic and genotypic features of Natural-Killer cell non-Hodgkin's lymphomas (NK-NHL). Cytotoxic cells, including NK cells and cytotoxic αβ and γδ T lymphocytes may induce lysis of the target by using granule-associated cytotoxic proteins such as the T-cell intracellular antigen-1 (TIA-1), perforin and granzyme B. Expression of TIA-1 can be detected in all cytotoxic cells whereas granzyme B and perforin expression can be detected in high levels only in activated cytotoxic cells. Recently, several studies showed that the expression of these cytotoxic proteins in tumour cells of PTCL and NK-NHL is associated with a) extranodal site of clinicopathological presentation b) NK or Tγδ-cell phenotype c) CD30 expression in cutaneous T-cell lymphoproliferations and d) anaplastic morphology in nodal PTCL. This latter finding contrasts with the data that only rare Hodgkin lymphomas (HL) express cytotoxic proteins in Hodgkin and Reed-Sternberg cells. Altogether the data of the literature indicate that most extranodal T and NK-NHL are activated cytotoxic lymphomas with the notable exception of hepatosplenic γδ PTCL which represent tumours of non-activated cytotoxic cells. On this basis, it is suggested that the expression of cytotoxic proteins may be useful for the identification and classification of extranodal T and NK-cell lymphomas and, to some extent, for the differential diagnosis between HL and CD30+ anaplastic large cell lymphomas. Cytotoxic lymphomas are preferentially localized in extranodal sites such as skin, lung, upper respiratory and gastrointestinal tracts, which are continuously exposed to various antigens. Since cytotoxic T and NK cells are regarded as first line of defense in these sites, and some cytotoxic tumours such as nasal lymphomas and enteropathy-type intestinal lymphomas are associated with EBV and gliadin, respectively, it is likely that chronic antigen exposure may play a role in the pathogenesis of cytotoxic lymphomas occurring in mucosa and/or skin. Besides chronic antigenic stimulation, chronic immunosuppression may also have pathogenetic significance in cytotoxic lymphomas in view of their increased incidence in immunocompromised patients.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Low-Protein Diet Induces IRE1α-Dependent Anticancer Immunosurveillance
Rubio-Patiño C., Bossowski J.P., De Donatis G.M., Mondragón L., Villa E., Aira L.E., Chiche J., Mhaidly R., Lebeaupin C., Marchetti S., Voutetakis K., Chatziioannou A., Castelli F.A., Lamourette P., Chu-Van E., Fenaille F., Avril T., Passeron T., Patterson J.B., Verhoeyen E., Bailly-Maitre B., Chevet E., Ricci J.-E. (2018)Dietary restriction (DR) was shown to impact on tumor growth with very variable effects depending on the cancer type. However, how DR limits cancer progression remains largely unknown. Here, we demonstrate that feeding ... -
Indoleamine 2,3-dioxygenase downregulates T-cell receptor complex ζ-chain and c-Myc, and reduces proliferation, lactate dehydrogenase levels and mitochondrial glutaminase in human T-cells
Eleftheriadis T., Pissas G., Antoniadi G., Tsogka K., Sounidaki M., Liakopoulos V., Stefanidis I. (2016)Indoleamine 2,3-dioxygenase (IDO), through L-tryptophan depletion, activates general control non-derepressible (GCN) 2 kinase and suppresses T-cell proliferation, in addition to suppressing aerobic glycolysis and glutaminolysis, ... -
Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: Is there a role in clinical practice?
de Mello R.A., Zhu J.-H., Iavelberg J., Potim A.H., Simonetti D., Júnior J.A.S., Castelo-Branco P., Pozza D.H., Tajima C.C., Tolia M., Antoniou G. (2020)[No abstract available]